ABCL250417P5000
- 2.49
- 0.000.00%
AbCellera Biologics Newsroom
Express News | Abcellera Biologics Inc : Leerink Partners Cuts Target Price to $5 From $7
KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $5
Keybanc Maintains Overweight on AbCellera Biologics, Raises Price Target to $5
Institutions Profited After AbCellera Biologics Inc.'s (NASDAQ:ABCL) Market Cap Rose US$92m Last Week but Individual Investors Profited the Most
AI-focused Drug Discovery Firms Rise as FDA Phases Out Animal Testing
AbCellera to Participate at Upcoming Investor Conferences in May and June
Press Release: AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
AbCellera Announces Presentation of In Vivo Data on PSMA X CD3 T-Cell Engagers at AACR 2025
Insider Purchase: Director at $ABCL Buys 25,000 Shares
John Montalbano Bought 66% More Shares In AbCellera Biologics
Director Makes Bold Move With Major Stock Purchase in AbCellera Biologics
Bloom Burton Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $9
Analysts Have Conflicting Sentiments on These Healthcare Companies: Castle Biosciences (CSTL), AbCellera Biologics (ABCL) and Apellis Pharmaceuticals (APLS)
Benchmark Co. Maintains AbCellera Biologics(ABCL.US) With Hold Rating
AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
AbCellera Biologics' Earnings Call: Transition Amid Challenges
AbCellera Biologics Analyst Ratings
Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Cuts Target Price to $10
Express News | Abcellera Biologics Inc : Stifel Cuts Target Price to $10 From $12
Earnings Call Summary | AbCellera Biologics(ABCL.US) Q4 2024 Earnings Conference